Latest Ratios: P/E Ratio -7.2x · EV/EBITDA N/A · ROE -26.1%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $581M | $317M | $379M | — | — | — |
| Enterprise Value | $513M | $249M | $363M | — | — | — |
| P/E Ratio → | -7.16 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 1.65 | 1.21 | 1.91 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | — | -32.2% | — | — |
| Net Profit Margin | — | — | — | 45.4% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -26.1% | -26.1% | -64.9% | — | -48.1% | -47.1% |
| ROA | -24.5% | -24.5% | -24.6% | 25.1% | -40.0% | -41.1% |
| ROIC | -27.1% | -27.1% | -26.1% | -16.2% | -33.6% | — |
| ROCE | -29.0% | -29.0% | -31.1% | -19.1% | -41.3% | -42.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | — | 0.15 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.08 | — | 0.01 | 0.00 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | 9.38 | — | — |
| Interest Coverage | — | — | — | 112.39 | -61.51 | -86.35 |
Net cash position: cash ($76M) exceeds total debt ($8M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 27.50 | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Quick Ratio | 27.50 | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Cash Ratio | 26.98 | 26.98 | 20.53 | 22.83 | 6.26 | 18.78 |
| Asset Turnover | — | — | — | 0.38 | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $28M | $26M | $25M | $25M | $25M |
Clinical trial execution dependency
According to recent market data, Contineum trades at a P/B of 1.51, which suggests that investors are heavily discounting the company's intangible assets while awaiting clinical validation of its lead CNS-penetrant pipeline assets, a valuation profile typical of early-stage biotechnology firms lacking commercial revenue streams.
The absence of a meaningful P/E or P/S ratio underscores that the market is currently pricing the company as a series of contingent options rather than a going concern. This valuation gap relative to peers like ACADIA suggests that the market may be waiting for definitive Phase 2 data before assigning a premium to the company's proprietary molecular engineering platform.
Based on reported financial figures, Contineum's ROIC has remained consistently negative, hovering around -5.9% in 2026Q1, which highlights the structural challenge of compounding returns when the primary capital allocation is directed toward high-cost clinical trials rather than revenue-generating commercial activities.
The volatility in ROIC, which saw a brief spike to 36.1% in 2024Q4, appears to be an accounting anomaly rather than a reflection of operational efficiency. Investors should monitor the company's ability to stabilize these returns as it moves closer to potential commercialization, as current trends indicate a persistent decay in capital productivity.
As reported in financial statements, Contineum's current ratio has experienced significant compression, falling from 38.00 in 2026Q1 to lower levels, which indicates that the company's liquidity position is becoming increasingly strained as it funds its ongoing clinical development programs without offsetting cash inflows.
While the current ratio remains technically high, the rapid depletion of cash reserves suggests that the company's operational runway is narrowing faster than anticipated. This trend warrants close monitoring, as the firm may be forced to seek dilutive financing sooner than the market currently expects to maintain its clinical momentum.
As indicated by the company's financial profile, the P/B ratio is the most commonly misapplied metric for Contineum, as it fails to capture the value of the company's intellectual property and clinical pipeline, which are the primary drivers of its long-term economic potential.
Investors should instead focus on the cash burn rate relative to clinical milestones, as the P/B ratio obscures the reality that the company's tangible assets are negligible compared to the value of its proprietary CNS-penetrant molecular scaffolds. Relying on book value in this context may lead to a fundamental misunderstanding of the company's true risk-reward profile.
Includes 30+ ratios · 5 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTNM stock.
Contineum Therapeutics, Inc. Class A Common Stock's current P/E ratio is -7.2x. This places it at the 50th percentile of its historical range.
Contineum Therapeutics, Inc. Class A Common Stock's return on equity (ROE) is -26.1%. The historical average is -46.6%.
Based on historical data, Contineum Therapeutics, Inc. Class A Common Stock is trading at a P/E of -7.2x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.